Drugs / THDB0206
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07257627 | Apr → Dec 2024 | — | Tonghua Dongbao Pharmaceutical Co.,Ltd | Completed | No outcome recorded |
| Phase 1 | NCT06153329 | Jun 2021 → Jun 2022 | — | Tonghua Dongbao Pharmaceutical Co.,Ltd | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT05834868 | May 2022 → Dec 2024 | type 2 diabetes mellitus | Tonghua Dongbao Pharmaceutical Co.,Ltd | Completed | No outcome recorded |
| Phase 3 | NCT07282054 | Apr 2022 → Jan 2025 | type 1 diabetes mellitus | Tonghua Dongbao Pharmaceutical Co.,Ltd | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | THDB0206 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05834868 ↗ |
| Route | Subcutaneous | “Injected subcutaneously three times a day.” NCT05834868 ↗ |